Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alexion Buys Taligen, Adding A Complement To Its Research Pipeline

This article was originally published in The Pink Sheet Daily

Executive Summary

Alexion acquired the privately-held biotech for $111 million plus milestone payments

You may also be interested in...



GSK Will Be A Limited Partner In Sanderling Ventures’ New Fund

The pharma pledges $50 million to the California firm’s new seventh round, which it anticipates closing more than eight years after its sixth. For GSK, it’s the latest tie-up with a VC firm as part of a regional investment strategy.

With Trio Of 2011 Deals, Alexion Looks To Nearly Double R&D Spending In 2012

The biotech, which is enjoying growing sales of high-priced, ultra-orphan terminal complement inhibitor Soliris, also has a pipeline of four other clinical and preclinical candidates for rare diseases.

Alexion Pumps Up Its Rare Disease Portfolio With Enobia Acquisition

Alexion could pay as much as $1.08 billion for access to Enobia's mid-stage rare disease compound asfotase alpha.

Related Content

Topics

UsernamePublicRestriction

Register

PS071767

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel